COVID-19 Update: We are currently shipping orders daily. However, due to transit disruptions in some geographies, deliveries may be delayed. To provide all customers with timely access to content, we are offering 50% off Science and Technology Print & eBook bundle options. Terms & conditions.
New Targeting in The Reversal of Resistant Glioblastomas - 1st Edition - ISBN: 9780128225271

New Targeting in The Reversal of Resistant Glioblastomas

1st Edition

0.0 star rating Write a review
Editor: Ali Syed Arbab
Hardcover ISBN: 9780128225271
Imprint: Academic Press
Published Date: 1st January 2021
Page Count: 309
Sales tax will be calculated at check-out Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

  1. Current status of recurrent glioblastoma therapies
    Ali S. Arbab
    2. Imaging of glioblastoma recurrence
    Scott E. Forseen, MD, Bruce C. Gilbert, MD, and Ramon E. Figueroa, MD, FACR
    3. Overarching therapeutic challenges and arachidonic acid metabolism as a novel target in glioblastoma
    Thaiz F. Born, PhD and B.R. Achyut, PhD
    4. The intervention of IL-8-CXCR2 axis to reverse the resistance to GBM therapies
    Kartik Angara, PhD, Mohammad H Rashid, MBBS, PhD, Ali S. Arbab, MD, PhD
    5. Targeting Glioma Stem Cell Metabolism to Enhance Therapy Responses and Minimize Resistance
    Raffaella Spina and Eli E. Bar, PhD
    6. Pros and cos of immunotherapy
    Shahidul Islam, MBBS, PhD
    7. Glioblastoma resistance and convection therapy
    Jonathan Sherman, MD
    8. Sensitization of resistant GBM to radiation
    Waaqo Daddacha, PhD

Description

New Targeting in The Reversal of Resistant Glioblastomas discusses alternative treatment strategies that not only target tumor cells but also target the tumor microenvironment, metabolic pathways and interaction of cytokines in tumor cells. The current treatment for primary and recurrent glioblastomas is failing because clinicians are not considering the effect of bone marrow derived cells to the development of resistance to clinically practiced therapies. This book helps readers rethink treatment strategies to successfully fight glioblastomas. It is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field.

Key Features

  • Explains the effect of bone marrow derived cells on the development of resistance to clinically practiced therapies
  • Provides information on the availability of alternate therapies for recurrent glioblastoma when standard practices have failed
  • Discusses targeting tumor microenvironment using available FDA approved drugs as an alternative treatment strategy for glioblastoma

Readership

Cancer researchers, medical scientists, clinicians, graduate students


Details

No. of pages:
309
Language:
English
Copyright:
© Academic Press 2021
Published:
1st January 2021
Imprint:
Academic Press
Hardcover ISBN:
9780128225271

Ratings and Reviews


About the Editor

Ali Syed Arbab

Ali Syed Arbab, MD PHD, is Leader of Tumor Angiogenesis Initiative and Director, Core Imaging Facilities for Small Animals, both at Augusta University. Dr. Arbab’s laboratory is devoted to determining the mechanisms of therapy resistance by focusing on the involvement of bone marrow derived cells in modulating the tumor microenvironment and initiating tumor neovascularization in glioblastoma models. To understand the involvement of bone marrow cells in developing resistance to antiangiogenic therapies (AAT), his group has developed chimeric animal models where bone marrow of the recipient animal is replaced with GFP+ bone marrow. Dr. Arbab’s group documented that tumor-recruited bone marrow cells are a predominantly heterogeneous myeloid cell population that can predict therapeutic response in cancer, and they are using several strategies to target bone marrow or tumor-promoting myeloid cells to potentiate the anti-tumor effect of FDA-approved drugs in preclinical models of glioblastoma.

Affiliations and Expertise

Leader of Tumor Angiogenesis Initiative and Director, Core Imaging Facilities for Small Animals, Augusta University, Georgia